Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOGNASDAQ:ATXSNASDAQ:CMPSNASDAQ:HRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.38-3.0%$6.65$3.75▼$11.40$150.27M2.79102,456 shs79,338 shsATXSAstria Therapeutics$5.99+14.8%$4.51$3.56▼$12.92$338.04M0.39373,356 shs664,913 shsCMPSCOMPASS Pathways$4.80+6.0%$3.72$2.49▼$8.54$449.10M2.25864,138 shs1.21 million shsHRTXHeron Therapeutics$2.10+5.0%$2.02$1.04▼$3.93$320.38M1.152.25 million shs1.71 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition0.00%-0.21%+26.76%+76.65%+937,999,900.00%ATXSAstria Therapeutics0.00%+29.09%+35.09%-3.23%-34.75%CMPSCOMPASS Pathways0.00%+15.94%+27.63%+28.34%-35.74%HRTXHeron Therapeutics0.00%+11.11%-3.45%-12.13%-45.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACOGAlpha Cognition1.0066 of 5 stars3.50.00.00.00.00.80.0ATXSAstria Therapeutics1.615 of 5 stars3.61.00.00.01.91.70.0CMPSCOMPASS Pathways2.0207 of 5 stars3.51.00.00.03.40.80.6HRTXHeron Therapeutics3.7256 of 5 stars3.50.00.04.23.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00113.22% UpsideATXSAstria Therapeutics 3.25Buy$30.00400.83% UpsideCMPSCOMPASS Pathways 3.00Buy$18.83292.36% UpsideHRTXHeron Therapeutics 3.00Buy$5.50161.90% UpsideCurrent Analyst Ratings BreakdownLatest ACOG, HRTX, ATXS, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$12.005/16/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/14/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.005/13/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.004/29/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$47.004/11/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/31/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/25/2025ACOGAlpha CognitionRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha Cognition$2.93M51.31N/AN/A($1.08) per share-8.69ATXSAstria TherapeuticsN/AN/AN/AN/A$3.33 per shareN/ACMPSCOMPASS PathwaysN/AN/AN/AN/A$3.65 per shareN/AHRTXHeron Therapeutics$148.52M2.16N/AN/A($0.23) per share-9.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$13.77M-$1.20N/A∞N/AN/AN/A-344.17%8/11/2025 (Estimated)ATXSAstria Therapeutics-$72.89M-$1.87N/AN/AN/AN/A-43.58%-29.36%8/11/2025 (Estimated)CMPSCOMPASS Pathways-$118.46M-$1.99N/AN/AN/AN/A-63.85%-51.97%7/30/2025 (Estimated)HRTXHeron Therapeutics-$110.56M-$0.06N/AN/AN/A-20.31%N/A-12.72%8/5/2025 (Estimated)Latest ACOG, HRTX, ATXS, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACOGAlpha Cognition-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million5/13/2025Q1 2025ATXSAstria Therapeutics-$0.48-$0.58-$0.10-$0.58N/AN/A5/8/2025Q1 2025CMPSCOMPASS Pathways-$0.47-$0.44+$0.03-$0.24N/AN/A5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million3/31/2025Q4 2024ACOGAlpha Cognition-$0.48-$0.51-$0.03-$0.51N/AN/A3/11/2025Q4 2024ATXSAstria Therapeutics-$0.45-$0.44+$0.01-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AATXSAstria TherapeuticsN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A1.501.50ATXSAstria TherapeuticsN/A22.3822.38CMPSCOMPASS Pathways0.158.918.91HRTXHeron TherapeuticsN/A2.281.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AATXSAstria Therapeutics98.98%CMPSCOMPASS Pathways46.19%HRTXHeron Therapeutics80.01%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%ATXSAstria Therapeutics4.50%CMPSCOMPASS Pathways3.93%HRTXHeron Therapeutics5.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.02 million10.97 millionN/AATXSAstria Therapeutics3056.43 million54.80 millionOptionableCMPSCOMPASS Pathways12093.56 million65.51 millionOptionableHRTXHeron Therapeutics300152.56 million143.33 millionOptionableACOG, HRTX, ATXS, and CMPS HeadlinesRecent News About These CompaniesHeron Therapeutics (NASDAQ:HRTX) Upgraded by Wall Street Zen to Buy RatingJune 7 at 12:35 AM | marketbeat.comNuveen Asset Management LLC Reduces Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)June 6 at 3:26 AM | marketbeat.comTwo Sigma Investments LP Sells 411,906 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)June 4, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Stock Rating Lowered by Wall Street ZenMay 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases Shares of 3,075,809 Heron Therapeutics, Inc. (NASDAQ:HRTX)May 22, 2025 | marketbeat.comStonepine Capital Management LLC Invests $1.07 Million in Heron Therapeutics, Inc. (NASDAQ:HRTX)May 20, 2025 | marketbeat.comTang Capital Management LLC Boosts Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)May 20, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 660,971 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)May 19, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 135,722 Heron Therapeutics, Inc. (NASDAQ:HRTX)May 15, 2025 | marketbeat.comJ. Goldman & Co LP Acquires Shares of 270,100 Heron Therapeutics, Inc. (NASDAQ:HRTX)May 14, 2025 | marketbeat.com300,000 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Bought by Bridgeway Capital Management LLCMay 14, 2025 | marketbeat.comQ2 Earnings Estimate for HRTX Issued By Northland CapmkMay 10, 2025 | marketbeat.comClearline Capital LP Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)May 10, 2025 | marketbeat.comResults: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 9, 2025 | finance.yahoo.comHeron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Beats Expectations By $0.03 EPSMay 8, 2025 | marketbeat.comHeron Therapeutics Target of Unusually High Options Trading (NASDAQ:HRTX)May 8, 2025 | marketbeat.comEarnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surgesMay 7, 2025 | investing.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call TranscriptMay 7, 2025 | insidermonkey.comHeron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ...May 7, 2025 | finance.yahoo.comHeron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate UpdatesMay 6, 2025 | finanznachrichten.deHeron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACOG, HRTX, ATXS, and CMPS Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.38 -0.29 (-3.00%) As of 06/6/2025 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Astria Therapeutics NASDAQ:ATXS$5.99 +0.77 (+14.75%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$6.00 +0.00 (+0.08%) As of 06/6/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.COMPASS Pathways NASDAQ:CMPS$4.80 +0.27 (+5.96%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$4.76 -0.04 (-0.92%) As of 06/6/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Heron Therapeutics NASDAQ:HRTX$2.10 +0.10 (+5.00%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$2.07 -0.03 (-1.43%) As of 06/6/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
